ArticleArchives of Razi Institute2024
Sericin-Induced Hypophagia Mediates Via M1 Muscarinic, NMDA Glutamate and Glycine Receptors in Neonatal Chicken.
Article in Archives of Razi Institute, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study was to ascertain the interaction between muscarinic, NMDA glutamate, and glycine receptors on sericin-induced hypophagia in neonatal chickens. This study comprised six experiments, with four groups in each and 11 repeats per group. In Experiment 1, the chicken received an ICV injection of saline, sericin (0.5 nmol), or Telenzepine (an M1 muscarinic receptor antagonist, 125 nmol). Group 4 received a co-injection of sericin and Telenzepine. In experiments 2-6, the chicken received ICV injections of AF-DX116 (an M2 muscarinic receptor antagonist, 125 nmol), 4-DAMP (an M3 muscarinic receptor antagonist, 125 nmol), PD102807 (an M4 muscarinic receptor antagonist, 125 nmol), MK-801 (an NMDA glutamate receptor antagonist, 15 nmol), and strychnine (a glycine receptor antagonist, 100 nmol) instead of Telenzepine. Subsequently, the cumulative food intake was quantified at 30, 60, and 120 minutes post-injection. The results demonstrated that the ICV injection of sericin (0.5 nmol) led to a notable reduction in cumulative food intake when compared to the control group (P<0.05). The co-injection of telenzepine and sericin resulted in a notable reduction in the hypophagia induced by sericin, as evidenced by a statistically significant difference (P<0.05). The co-injection of MK-801 and sericin resulted in a reduction of the hypophagic effects of sericin when compared to the control group (P<0.05). The co-injection of strychnine and sericin resulted in a notable reduction in the hypophagic effects of sericin, as evidenced by a statistically significant difference when compared to the control group (P<0.05). These findings suggest that sericin-induced hypophagia is mediated via M1 muscarinic, NMDA glutamate, and glycine receptors in neonatal chickens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.